Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism  by Klok, F.A. et al.
Respiratory Medicine (2010) 104, 1744e1749ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedPrevalence and potential determinants of
exertional dyspnea after acute pulmonary embolismF.A. Klok a,*, K.W. van Kralingen b, A.P.J. van Dijk c, F.H. Heyning d,
H.W. Vliegen e, M.V. Huisman aa Section of Vascular medicine, Department of General Internal Medicine-Endocrinology, LUMC (C4-70), Albinusdreef 2,
Postbus 9600, 2300 RC Leiden, The Netherlands
bDepartment of Pulmonary Medicine, LUMC, Leiden, The Netherlands
cDepartment of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
dDepartment of Hematology, Medical Center Haaglanden, The Hague, The Netherlands
eDepartment of Cardiology, LUMC, Leiden, The Netherlands
Received 30 January 2010; accepted 8 June 2010KEYWORDS
Pulmonary embolism;
Dyspnea;
Long term follow-up;
Pulmonary
hypertension;
Echocardiography;
Exercise test* Corresponding author. Tel.: þ31 7
E-mail address: f.a.klok@lumc.nl (
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.06.006Summary
Background: The exact prevalence and etiology of exertional dyspnea in the clinical course of
acute pulmonary embolism (PE) have not yet been established.
Methods: A large cohort of consecutive patients diagnosed with acute PE was subjected to
a dyspnea questionnaire and invited for cardiopulmonary work-up including the 6-min walk
test, spirometry and echocardiography. The prevalence, severity, determinants and underlying
diseases of exertional dyspnea were evaluated.
Results: Of the registered 877 patients, 259 (30%) had died and 11 (1.3%) were excluded for
geographical reasons. From the remaining 607 patients, 217 reported exertional dyspnea
(36%; 95% CI 32e40%) 3.6  1.7 years after the PE. In 76% this dyspnea had developed or wors-
ened after the acute PE. 421 patients completed the cardiopulmonary work-up. Cardiopulmo-
nary comorbidity (OR 12; 95% CI 6.5e20), advanced age (OR 1.02 per year; 95% CI 1.01e1.03),
higher BMI (OR 1.06 per kg/m2; 95% CI 1.01e1.1) and a smoking history (OR 1.6; 95% CI
1.02e2.6) were identified as independent predictors of exertional dyspnea. A pre-defined dys-
pnea explaining diagnosis could be established in all patients with exertional dyspnea. In only 4
patients, this diagnosis was directly correlated to the acute PE. Increased severity of dyspnea
was associated with decreased exercise performance (p < 0.001) and a higher number of dys-
pnea-related diagnoses (p < 0.001).
Conclusion: Exertional dyspnea is a frequent symptom in the long term clinical course of acute
PE. More severe dyspnea results in decreased exercise capacity and increased burden of1 5262085; fax: þ31 71 5248140.
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Epidemiology of exertional dyspnea after acute pulmonary embolism 1745cardiopulmonary comorbidity. This dyspnea is likely to be unrelated to the past thromboem-
bolic event in the vast majority of patients.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Dyspnea is a term used to characterize a subjective expe-
rience of breathing discomfort that is comprised of quali-
tatively distinct sensations that vary in intensity.1
Exertional dyspnea or breathing discomfort is a common
and distressing symptom expressed by patients and its
etiology may prove elusive.1e4 The majority of patients
with exertional dyspnea have one of four diagnoses:
asthma, chronic obstructive pulmonary disease (COPD),
interstitial lung disease or heart failure.2e4 Exertional
dyspnea after acute pulmonary embolism (PE) represents
a particular clinical challenge since this frequent observa-
tion requires distinguishing PE related from the above
stated causes of dyspnea. In recent studies, exertional
dyspnea was observed in 50e60% of the patients after they
were diagnosed with acute PE.5,6 Importantly, 70% of these
patients related their symptoms to the acute thromboem-
bolic event suggesting a causal relation between both.5 PE
associated conditions causing exertional dyspnea include
ventilationeperfusion mismatch leading to increased dead-
space ventilation or chronic thromboembolic pulmonary
hypertension (CTEPH) resulting from chronic emboli.5e9 A
third diagnosis could be recurrent PE, although these
patients present with more acute or sub-acute worsening
symptoms in the majority of cases.10,11 The relevance of
the distinction between PE and non-PE related disease
causing dyspnea is underlined by distinct differences in the
required diagnostic strategies, treatment and prognosis.
We sought to assess the exact prevalence and etiology of
exertional dyspnea in patients with prior acute PE. There-
fore, we have interviewed a large cohort of consecutive
patients surviving an acute episode of PE and in addition,
subjected these patients to a cardiopulmonary work-up.Methods
Patients
Consecutivepatientswhowerediagnosedwithacute PE in the
period between January 1st 2001 and July 1st 2007 in an
academic (Leiden University Medical Center, Leiden, the
Netherlands) and affiliated teaching hospital (Medical Center
Haaglanden, The Hague, The Netherlands) were studied.12
Eligible patients were identified from the hospital records of
the radiology department and the departments of internal,
pulmonary and emergencymedicine. Acute PEwas confirmed
bypulmonaryangiography, computed-tomographypulmonary
angiography (CTPA) or ventilationeperfusion scintigraphy
(VQ-scan).13Patientswere initially treatedwithat least5days
of either unfractionated or weight based therapeutic doses of
lowmolecular weight heparin, followed by oral anticoagulant
therapy for a period of at least 6 months. The current survival
status and contact information of each eligible patient wasretrieved from the hospital administrative database or local
municipal registries. All patients who survived until July 1st
2007 were telephonically interviewed for their detailed
medical history and the presence and severity of dyspnea.
Furthermore, they were invited for a single visit to our
vascular medicine outpatient clinic for cardiopulmonary
work-up including the 6-min walk test, spirometry and echo-
cardiography. This visit was scheduled between July 1st 2007
and January 1st 2009 and planned at least one full year after
the indexevent. Patientswhowerediagnosedwithpulmonary
hypertension prior to the start of our study were telephoni-
cally interviewed but not invited for a visit, since extensive
cardiopulmonary tests were already performed in the diag-
nostic work-up of these patients. This study was approved by
the institutional review board of both participating hospitals
and all patients provided informed consent.
Procedures
Patients were telephonically asked to complete a short
medical questionnaire that was specifically designed to
assess the presence, severity and possible causes of exer-
tional dyspnea in the clinical follow-up of patientswith acute
PE.5 In the patients who responded to our invitation for
a single visit to our outpatient clinic, the 6-min walk test was
performed in accordance with the ATS guidelines.14 Results
of this 6-min walk test are presented in percentage of the
reference standard.15 Ventilatory function was measured
using a turbine spirometer (Microlab 3300, Sensormedics. Ltd
Rochester, UK). Forced vital capacity (FVC), forced expira-
tory volume in 1 s (FEV1) and peak expiratory flow (PEF) were
measured until three reproducible recordings (with a differ-
ence of less than 5%) were obtained. The highest of these 3
values was used for analysis. A VIVID-I portable ultrasound
machine (GE Healthcare, Chalfont St. Giles, Bucks, UK) was
used for transthoracic echocardiography. Echocardiography
included cross sectional, M-mode and Doppler studies, and
was performed by an experienced technician according to
a standardized protocol. All echocardiographs were
reviewedby an independent expert cardiologist. If necessary
for establishing a diagnosis in symptomatic patients, further
routine clinical work-up consisting of laboratory, more
extensive pulmonary function or imaging tests were per-
formed under supervision of an independent expert panel. In
case of suspected pulmonary hypertension, this further
work-up included right heart catheterization at all times.
All included patients underwent standard as well as right
sided ECG analysis to exclude ischemic heart disease or
rhythm disturbances.
Outcome
Our primary endpoint was the prevalence of exertional
dyspnea as reported by patients surviving an episode of
acute PE. Our second endpoint was the assessment of
1746 F.A. Klok et al.determinants for the presence of exertional dyspnea in the
clinical follow-up of acute PE. We studied several variables
as possible determinants of exertional dyspnea in the
clinical course of acute PE. Length of the follow-up period,
centrally located PE, invasive treatment for PE (i.e.
administration of thrombolytic drugs, vena cava filter or
surgical removal of the embolus) and recurrent PE were
included as PE related determinants. Age, gender, body
mass index (BMI), smoking status and history of cardiopul-
monary disease other than PE were assessed as non-PE
related determinants. Our third endpoint included the
evaluation of the severity of the reported dyspnea. For the
purpose of this analysis, patients were classified according
to the criteria of the New York Heart Association (NYHA)
functional classification, although not strictly applicable to
a non-heart failure population.16 This classification
comprises 4 categories of increasing exercise impairment:
no limitation of physical activity by shortness of breath
(class I, no symptoms), ordinary physical activity results in
dyspnea (class II, mild symptoms), comfortable at rest, but
less than ordinary activity causes dyspnea (class III,
moderate symptoms) and symptoms of cardiac insufficiency
at rest, inability to carry out any physical activity without
discomfort (class IV, severe symptoms). In addition to the
NYHA classification, the total distance covered during the
6-min walk test and the modified Borg dyspnea scale after
the completion of the walk were considered to represent
the severity of the dyspnea and exercise intolerance.17 Our
final endpoint was the identification of the exact diagnoses
causing dyspnea following acute PE. We considered the
following diagnoses to be a sufficient justification for the
presence of exertional dyspnea: asthma diagnosed
according to the NIH guidelines, COPD classified as GOLD II
or worse in accordance with the NHLBI/WHO criteria,
significant restrictive pulmonary function impairment (FVC
< 80% and distinct restrictive flow curve), all cause
pulmonary hypertension, systolic or diastolic ventricular
dysfunction as stated in the ESC guidelines, significant
valvular disease according to the ACC/AHA guidelines,
anemia (woman < 7.4 mmol/l; man < 8.1 mmol/l) or
obesity (body mass index > 30 kg/m2).18e23 The presence of
further, PE related conditions as explanation for dyspnea
was considered unlikely if one or more of the above stated
diagnoses could be established.Statistical analysis
The overall prevalence of exertional dyspnea was assessed
for all patients who completed the medical questionnaire.
For the analysis of the further endpoints, we included the
patients who had completed the cardiopulmonary work-up.
Univariate relation between all possible determinants and
exertional dyspnea was assessed by calculating odds ratios
(OR) with 95% confidence intervals (95% CI). Univariate
analysis was followed by multivariate analysis to identify
the independent determinants of exertional dyspnea. For
this, a conditional logistic regression model was used
evaluating all possible determinants. Fisher’s analysis of
variance (ANOVA) with least significant difference post-hoc
tests was used to detect differences among the 4 NYHA
classes. A p-value <0.05 was used to define statisticalsignificance. SPSS version 14.02 (SPSS Inc, Chicago, IL) was
used for all analysis.Results
Patients and prevalence of dyspnea
In total, 877 patients were diagnosed with acute PE
between January 1st 2001 and July 1st 2007 in the two
participating hospitals. Of these, 259 (30%) had died before
July 1st 2007 and 11 patients (1.3%) were lost to follow-up.
Deaths were attributed to malignancies in 110 patients
(13%), (recurrent) PE in 67 patients (7.7%), bleeding from
anticoagulant therapy in 6 patients (0.69%), cardiovascular
disease in 30 patients (3.5%), non-malignant pulmonary
disease in 11 patients (1.3%) and other causes in 35 patients
(4.2%). The remaining 607 patients were successfully con-
tacted after a median period of 3.6 years (interquartile
range 2.1e5.1 years). Of those, 30 (4.9%) declared to be
in excellent health with no dyspnea, but refused to
complete the questionnaire. An additional 156 patients
declined visiting our hospital for further cardiopulmonary
work-up. Finally, 19 patients were diagnosed with pulmo-
nary hypertension prior to the start of our study. Pulmonary
function tests, echocardiography and the 6-min walk
test were routinely performed in these patients, and
therefore these patients were not invited for further
cardiopulmonary work-up. The remaining 402 patients
visited our outpatient clinic and completed the cardiopul-
monary function tests.
On questioning, 217 of the surviving patients reported
dyspnea, resulting in an overall dyspnea prevalence of 36%
(217/607; 95% CI 32e40%). From the 217 patients reporting
dyspnea, 165 (76%) specified that the dyspnea had devel-
oped or worsened after the acute PE.
Predictors of dyspnea
The general characteristics at diagnosis of PE of the 421
patients with complete cardiopulmonary data, i.e. 19
patients previously diagnosed with pulmonary hypertension
and 402 who completed the cardiopulmonary work-up, are
depicted in Table 1: mean age was 55 years, 225 (53%) were
males, 143 (34%) were diagnosed with centrally located PE,
23 (5.5%) patients had received invasive treatment for the
PE, recurrent VTE was diagnosed in 64 (15%) patients, 116
(28%) were previously diagnosed with cardiopulmonary
disease, mean BMI was 28 kg/m2 and 255 (61%) patients were
current or former smokers. Univariate analysis indicated that
none of the PE related factors was a predictor of dyspnea. In
contrast, advanced age, larger BMI, smoking and a history of
cardiopulmonary disease were all significantly predictive for
dyspnea (Table 1). Importantly, the follow-up period was not
different between patients with and without dyspnea (mean
3.4 years [interquartile range 1.9e4.8] vs. 3.8 years [inter-
quartile range 2.1e5.3] respectively). After multivariate
analysis, a history of cardiopulmonary disease (OR 12, 95% CI
6.5e20), advanced age (OR 1.02 per year, 95% CI 1.01e1.03),
higher BMI (OR 1.06 per kg/m2, 95% CI 1.01e1.1) and
a smoking history (OR 1.6, 95% CI 1.02e2.6) at diagnosis were
Table 1 Characteristics of the patients who completed the cardiopulmonary work-up at diagnosis of PE.
All
patients
n Z 421
No dyspnea
reported
n Z 232
Dyspnea
present
n Z 189
ORa for dyspnea
(per unit for continuous
variables) (95% CI)
Age (years  SD) 55  16 52  16 58  16 1.02 (1.01e1.04)
Male sex (n, %) 225 (53) 127 (55) 98 (52)
Central localization first PE (n, %) 143 (34) 78 (34) 65 (34)
Thrombolysis, Surgery or VCF for first acute PE (n, %) 23 (5.5) 13 (5.6) 10 (5.3)
Recurrent VTE (n, %) 64 (15) 30 (13) 34 (18)
Known history of cardiopulmonary disease (n, %) 116 (28) 22 (9.5) 94 (50) 10.4 (6.1e18)
Body Mass Index (kg/m2  SD) 28  5.3 28  6.0 29  5.1 1.05 (1.01e1.1)
Smoking history
Current (n, %) 77 (18) 41 (18) 36 (19)
Former (n, %) 178 (42) 93 (40) 85 (45)
Never (n, %) 166 (39) 100 (43) 66 (35) 0.64 (0.43e0.96)
Number of pack years (mean  SD) 14  17 10  13 18  20 1.03 (1.02e1.04)
PEZ Pulmonary embolism, VCFZ vena cava filter, VTEZ venous thromboembolism, SDZ standard deviation, nZ number, ORZ odds
ratio, CI Z confidence interval.
a Only for significant determinants of dyspnea after univariate analysis.
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dyspnea after acute PE.Severity and causes of dyspnea
Of the 421 patients with complete cardiopulmonary data,
189 reported dyspnea (45%, 95% CI 40e50%): 151 (80%, 95%
CI 73e85%) were classified as NYHA II, 31 (16%, 95% CI
11e22%) as NYHA III and 7 (3.7%, 95% CI 1.5e7.5) as NYHA
IV. The mean percentage of predicted walking distance in
the 6-min walk test decreased in subsequent NYHA classes:
99  11% in NYHA class I, 96  12% in NYHA II class, 77  21%
in NYHA III class and 35  8.4% in NYHA IV class (p Z 0.017
for the first step, p < 0.001 for the last 2 steps). In addition
to this observation, the modified Borg dyspnea score after
the 6 min walk test increased in the subsequent NYHA
classes: 1.2  1.1, 2.5  1.5, 4.6  1.8 and 6.6  1.3
respectively (p < 0.001 for the first 2 steps, p Z 0.002 forTable 2 Causes of dyspnea in the clinical course of acute pulmo
dyspnea-related disease.
NYHA
n Z
Asthma (n, %) 5 (2
COPDa (n, %) 6 (2
Restrictive pulmonary function impairment (n, %) 10 (4
Pulmonary hypertension (other than CTEPH; n, %) 0 (0
CTEPH (n, %) 0 (0
Systolic cardiac dysfunction (n, %) 6 (2
Diastolic cardiac dysfunction (n, %) 66 (2
Significant valvular heart disease (n, %) 1 (0
Anemia (n, %) 8 (3
Obesityb (n, %) 65 (2
COPD Z chronic obstructive pulmonary disease, n Z number.
a Classification GOLD II or worse.
b body mass index > 30 kg/m2.the last step). The 6-min walk test could not be performed
in 47 patients because of immobility or other reasons.
The final dyspnea-related diagnoses established in the
study patients are presented in Table 2. All patients with
exertional dyspnea were diagnosed with at least one of the
pre-defined dyspnea explaining conditions. On average,
patients in NYHA class II were diagnosed with 1.5, in NYHA
class III with 3.0 and patients in NYHA class IV with 3.4
different diagnoses (p < 0.001). Only in 4 patients this
diagnosis could be causally related to the past acute PE.
These patients were diagnosed with CTEPH after right
heart catheterization and pulmonary angiography. CTEPH
was ruled out in the remaining 25 patients with pulmonary
hypertension after perfusion scintigraphy or pulmonary
angiography. Seven of these 25 patients had COPD associ-
ated pulmonary hypertension, 9 had left sided ventricular
or valvular heart disease, 4 had idiopathic pulmonary
hypertension and 5 pulmonary fibrosis. Notably, the prev-
alence of dyspnea-related diagnoses in asymptomaticnary embolism. Patients can be diagnosed with more than one
I
232
NYHA II
n Z 151
NYHA III
n Z 31
NYHA IV
n Z 7
.2) 12 (7.9) 3 (9.7) 1 (14)
.6) 29 (19) 13 (42) 3 (43)
.3) 9 (6.0) 1 (3.2) 1 (14)
) 5 (3.3) 17 (55) 3 (43)
) 1 (0.66) 3 (9.7) 0 (0)
.6) 19 (13) 11 (68) 3 (43)
8) 59 (39) 19 (35) 5 (71)
.43) 3 (2.0) 2 (6.5) 2 (29)
.4) 26 (17) 4 (13) 1 (14)
8) 50 (33) 18 (58) 3 (43)
1748 F.A. Klok et al.patients was 47%, mainly as a result of 66 cases of diastolic
ventricular dysfunction.
In total, 113 patients with dyspnea reported this symptom
to be developed after the PE was diagnosed. From those
patients, 3 were classified as NYHA class IV, 18 as NYHA class
III and 92 as NYHA class II. The most prevalent dyspnea-
related diagnoses in these patients were diastolic cardiac
dysfunction (nZ 49), obesity (nZ 42) and COPD (nZ 23).Discussion
This study demonstrates that the prevalence of exertional
dyspnea long after acute PE is 36%. This dyspnea was
however not related to the past thromboembolic event in
the vast majority of the patients. The clinical relevance of
the subjective symptom of shortness of breath is under-
scored by the decreased exercise tolerance and increased
prevalence of dyspnea-related comorbidity that we found
in patients who presented with more severe symptoms.
Although we observed that the majority of symptomatic
patients correlated their exertional dyspnea to the acute PE,
we could not establish pathophysiological grounds for this
observation for two important reasons. First, single and
multivariate analysis excluded pre-defined PE related char-
acteristics as determinants for the presence of exertional
dyspnea. Second, the includedpatients underwent extensive
cardio- andpulmonary-function tests. PE relateddiseasewas
identified in only 4 patients and all remaining symptomatic
patients could be diagnosed with at least one non-PE related
dyspnea explaining condition. We therefore hypothesized
that the psychological impact of this serious cardiovascular
event and the resulting deconditioning might very well
contribute to increased perception of dyspnea. Hence, it
would be interesting to study the effect of cardiopulmonary
rehabilitation programs to long term dyspnea and physical
fitness of patients with acute PE. Such programs have been
shown very effective after other acute cardiovascular
events, and may additionally improve quality of life in
patients after acute PE which is impaired compared to pop-
ulation controls.24e26 Also, our data suggest an effect of
smoking on the presence of dyspnea in the clinical course of
acute PE. Active stimulation of smoking cessation might
therefore helpful in preventing future dyspnea complaints,
and in addition, decrease the risk for cardiovascular events
which is increased in patients after acute PE.27,28
A different explanation for the reported temporal rela-
tion between PE and the occurrence or worsening of
dyspnea was provided by a previous study, that reported
either an abnormal right ventricular function on echocar-
diography or decreased exercise performance in 41% of
previously healthy patients 6 months after acute PE was
diagnosed.6 Notably, 15% of the patients with normal
baseline echocardiography had subsequently developed
right ventricular dysfunction during the follow-up period.
These findings suggest that a PE can cause persistent right
ventricular injury or initiate a pathophysiological process
damaging the right ventricle over time.6 Since our study
lacks baseline measurements of cardiac and pulmonary
function, we were unable to support this interesting
hypothesis. Although our results did not provide evidencefor unexplained right ventricular dysfunction on large scale
in our study population, this hypothesis also requires
further study.
Our results are in accordance with previous reports on
exertional dyspnea in other patient cohorts: the inde-
pendent determinants of dyspnea and the specific diag-
noses established in our study are comparable to those
described in the literature.1e4 Furthermore, our obser-
vation that patients with objectively confirmed dyspnea-
related disease as asthma or COPD did not report any
symptoms at all, is a well known phenomenon.1e4 None-
theless, some aspects of this study require comment.
First, a considerable number of eligible patients declined
visiting our hospital, reducing the external validity of our
results. Second, we could not put our results in
perspective due to the lack of a control population
without PE. Third, in patients who reported dyspnea
before the episode of acute PE, the presence of chronic
thromboembolism could not be ruled out. Likewise, since
we did not routinely screen for recurrent PE, persistent
pulmonary mismatch or chronic thromboembolism without
pulmonary hypertension at rest, these conditions might
be alternative explanations for the observed dyspnea.
Lastly, the risk of CTEPH after PE reported in this study is
lower than previously reported.7,8 This might be
explained by different selection and diagnostic criteria
applied in those studies, or by underdiagnosis of CTEPH in
our cohort. Indeed, due to our study design, objective
testing to rule out CTEPH could not be performed in all
study patients. Even so, the prevalence of dyspnea
among survivors of PE is considerably higher than the
prevalence of CTEPH. Since the diagnostic management
of CTEPH is complex and involves right heart catheteri-
zation, there is great need for future studies to focus on
the utilization of simple and noninvasive diagnostic tests
for ruling out this very serious condition.
In summary, exertional dyspnea is a frequent symptom
in the long term clinical course of acute PE. Increased
sensation of dyspnea is accompanied by higher burden of
cardiopulmonary comorbidity and decreased exercise
capacity. This dyspnea is unlikely to be related to PE in the
majority of patients. The clinical consequence of our study
is that exertional dyspnea in the clinical course of acute PE
is mainly caused by pre-existing comorbid conditions and
alarming direct complications of PE such as CTEPH are rare.
Nonetheless, physicians should remain alert on this serious
but potentially treatable disease.Contributors
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